Back to Blog
Bob hugin commercial5/20/2023 "Today's announcements reflect our Board's ongoing commitment to active board refreshment and governance best practices, as well as continuous engagement with our shareholders," said Mr. In addition, the Allergan Board of Directors today announced its intention to recommend FOR a pending shareholder proposal, which will also appear in Allergan's 2019 proxy statement, requiring an Independent Board Chair to be phased in during the next leadership transition. ![]() Hugin formerly served on the boards of Danaher Corporation, The Medicines Company, Coley Pharmaceutical Group and Atlantic Health System. Hugin is a member of the Board of Trustees of Princeton University, the Board of Trustees at the Darden School of Business at the University of Virginia and is past Chairman of the Board of The Pharmaceutical Research and Manufacturers of America. Hugin was instrumental in the strategic growth of the company, overseeing the expansion of Celgene from a U.S.-based biopharmaceutical company to a global company with operations in more than 50 countries. I look forward to contributing to the Board's effective, independent oversight of Allergan's strategy."Īs Chairman and Chief Executive Officer of Celgene Corporation, Mr. "In Allergan, I see a company with market leading positions in four therapeutic areas, a promising R&D pipeline and a focus on executing its business strategy. "I am excited to join the Allergan Board and begin working with Brent and the entire Board of Directors to create sustained value for shareholders," said Bob Hugin. I look forward to working with Bob and to Allergan benefitting from his expertise." ![]() "He has a strong track record of developing innovative therapies, delivering strong business results and creating shareholder value. Saunders, Chairman and Chief Executive Officer at Allergan. ![]() "Bob is an industry leader with deep operational, financial and commercial experience that is relevant to Allergan's business and strategy," said Brent L. Bob becomes the sixth new director we have added to the Board in the past two years as part of our transformation from a generic to a branded biopharmaceutical company." "With his extensive industry leadership and public company board experience, Bob will further strengthen our Board and augment its diverse set of skills and perspectives. "We are pleased to welcome Bob Hugin, a highly-regarded biopharmaceutical and business leader, to our Board of Directors," said Chris Coughlin, Lead Independent Director of Allergan's Board.
0 Comments
Read More
Leave a Reply. |